Tula Accelerating Innovation for a Cleaner, Greener Future
10.11.2021 12:00:00 EET | Business Wire | Press release
As world leaders gather in Glasgow for the 26th United Nations Climate Change Conference of the Parties (COP26) , there is once again a push for strategies to reach net zero by 2050 . With the transportation sector currently the fastest growing contributor to climate change and now accounting for almost a quarter of emissions, Tula Technology, Inc., a leader in propulsion efficiency, has accelerated the pace of innovation to reduce the environmental impact of passenger and commercial vehicles through its Dynamic Skip Fire (DSF®) and Dynamic Motor Drive (DMD™) technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110005156/en/
(Graphic: Business Wire)
“To reach net zero, OEMs are faced with meeting increasingly stringent emissions reductions standards,” said R. Scott Bailey, president and CEO of Tula Technology. “Tula has developed technologies that make it possible to achieve these mandates in a cost-effective manner. Whether we’re working with partners to reduce emissions in internal combustion engines or offering solutions to make electric vehicles more efficient, our team is committed to improving propulsion efficiency for a cleaner environment.”
The Tula Track Record of Innovation
- Using patented algorithms, DSF® chooses to skip or fire individual cylinders dynamically to meet an engine’s torque demands, enabling near-peak engine efficiency for a cleaner-burning, more fuel-efficient vehicle.
- DMD™ mitigates efficiency losses in electric motors while significantly reducing reliance on rare-earth materials. DMD’s application to electric vehicles (EVs) has the potential to increase range while using less energy. DMD is a cost-effective, software-driven solution. Without the need for rare earth materials, potential supply chain challenges and escalating costs can be avoided.
- A recent study of Tula’s DSF in a Class 8 truck powered by a Cummins X15 HD engine showed a 74 percent reduction in nitrogen oxides (NOX) and a 5 percent reduction in carbon dioxide (CO2). To demonstrate DSF in action, Tula recently released a “virtual test drive” video.
- FEV, an international engineering partner to the auto industry, joined Tula to evaluate Tula’s DSF for mild hybrid diesel vehicles and found an additional 11% of CO2 was eliminated compared to industry-leading hybrid powertrains. The CO2 reduction can be achieved at a cost of about $235 (€200) per vehicle. For manufacturers of light duty commercial vehicles, this technology offers a compelling and cost-effective solution to achieve challenging Euro 7 emission standards expected to go into effect by 2026 for all new vehicles in Europe.
- Tula and Jacobs Vehicle Systems signed an agreement and are working together to integrate DSF and Jacobs Cylinder Deactivation technology. Independent laboratory testing has demonstrated that Jacobs CDA hardware and Tula’s DSF achieve greater emission reductions when combined.
- Tula is partnering with Chinese vehicle equipment manufacturer E-Quality Tec, Inc. to embed DSF into E-Quality’s controller. Rapidly deploying fully integrated technology will enable medium and heavy-duty diesel vehicle manufacturers in China to aggressively target simultaneous reductions in both CO2 and NOX for CN Stage VI, China’s emission standard for heavy-duty vehicles.
- More than 1.5 million General Motors passenger vehicles are on the road in the U.S. utilizing DSF, each one saving roughly one ton of CO2 emissions each year, using the same cost-effective technology being deployed in commercial diesel and hybrid vehicles.
- Tula’s talented team members are on the cutting edge of automotive engineering, and recently were awarded their 200th global patent and have 378 patents issued or pending.
Tula is driven to improve efficiency across all manner of transportation and reduce emissions without sacrificing performance or comfort. We support immediate action on climate and clean air regulations to promote a sustainable future powered by innovation.
About Tula Technology, Inc.
Silicon Valley-based Tula Technology provides innovative award-winning software controls to optimize propulsion efficiency and emissions across the mobility spectrum, including gasoline-powered, diesel, alternative fuel, hybrid, and electric vehicles. Tula’s culture of innovation has resulted in breakthrough technology and a robust global patent portfolio of more than 378 patents issued and pending. Tula Technology is a privately held company backed by Sequoia Capital, Sigma Partners, Khosla Ventures, GM Ventures, BorgWarner and Franklin Templeton. More information is available at www.tulatech.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005156/en/
Contact information
Tula Technology, Inc.
Ram Subramanian
Principal Marketing Strategist
ram@tulatech.com
Media: Financial Profiles
Debbie Douglas, SVP
ddouglas@finprofiles.com
949-375-3436
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
